NEWARK, Calif., May 11, 2020 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage
biopharmaceutical company, today announced that it has commenced an
underwritten public offering of 5,000,000 shares of its common
stock. All of the shares of common stock are being offered by
Protagonist. In connection with this offering, Protagonist expects
to grant the underwriters a 30-day option to purchase up
to 750,000 additional shares of common stock.
Jefferies LLC and BMO Capital Markets Corp. are acting as joint
book-running managers for the offering. H.C. Wainwright & Co.,
LLC and Nomura Securities International, Inc. are acting as co-lead
managers for the offering. The offering is subject to market
conditions and there can be no assurance as to whether or when the
offering may be completed or the actual size or terms of the
offering.
A shelf registration statement relating to the offered shares of
common stock was filed with the Securities and Exchange
Commission (SEC) on October 31,
2019, and was declared effective on November 22, 2019. A preliminary prospectus
supplement and accompanying prospectus relating to the offering
will be filed with the SEC and will be available on the
SEC's website, located at www.sec.gov. Prospective investors
should read the preliminary prospectus supplement, when available,
and the accompanying prospectus and other documents we have filed
with the SEC for more complete information about us and
the offering. Copies of the prospectus supplement and the
accompanying prospectus related to the offering may be obtained,
when available, from Jefferies LLC Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at
877-547-6340 or by email at Prospectus_Department@Jefferies.com or
from BMO Capital Markets Corp., Attention: Equity Syndicate
Department, 3 Times Square, 25th Floor, New York, NY 10036, by telephone at
800-414-3627 or by email at bmoprospectus@bmo.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding Protagonist's expectations regarding the
completion, timing and size of the proposed public offering. In
some cases, you can identify these statements by forward-looking
words such as "expect," "may," "will," or the negative or plural of
these words or similar expressions (as well as other words or
expressions referencing future events, conditions or
circumstances). These forward-looking statements are based on
Protagonist's expectations and assumptions as of the date of this
press release. Each of these forward-looking statements involves
risks and uncertainties. Actual results may differ materially from
these forward-looking statements. These risks and uncertainties
include, without limitation, risks and uncertainties related to
market conditions and satisfaction of customary closing conditions
related to the proposed public offering. There can be no assurance
that Protagonist will be able to complete the proposed public
offering on the anticipated terms, or at all. Additional
information concerning these and other risks can be found in
Protagonist's periodic filings with the U.S. Securities and
Exchange Commission, including under the heading "Risk Factors"
contained therein, as well as the risks identified in the
registration statement and the preliminary prospectus supplement
relating to the offering. Any forward-looking statements that
Protagonist makes in this press release speak only as of the date
of this press release. Except as required by law, Protagonist
assumes no obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise,
after the date of this press release.
View original
content:http://www.prnewswire.com/news-releases/protagonist-therapeutics-inc-announces-proposed-underwritten-public-offering-of-common-stock-301056392.html
SOURCE Protagonist Therapeutics, Inc.